High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000305
Abstract: Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of unresectable melanoma on the basis of its overall survival (OS) benefit. However,… read more here.
Keywords: tumor samples; cytotoxic lymphocyte; akt expression; expression ... See more keywords